$0.17
(0.12%)
Add to watchlist
Create an alert
Stocks and Shares ISAGilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
Company Information
About this company
Key people
Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer
Keeley Wettan
Executive Vice President, General Counsel, Legal & Compliance
Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Dietmar P. Berger
Chief Medical Officer
Johanna Mercier
Chief Commercial Officer
Anthony Welters
Lead Independent Director
Jacqueline K. Barton
Independent Director
Jeffrey A. Bluestone
Independent Director
Sandra J. Horning
Independent Director
Kelly A. Kramer
Independent Director
Click to see more
Key facts
- Shares in issue1.24bn
- EPICGILD
- ISINUS3755581036
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$174.90bn
- Employees17,600
- ExchangeNASDAQ
- IndexS&P 500, NASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.